9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

Estimated reading time: < 1 min

Condition: Unresectable Pleural or Peritoneal Malignant Mesothelioma

Estimated Enrollment: 571

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Active, not recruiting

Study Results: Has Results

Outcome Measures: Overall Survival (OS),  OS Rate at 18 Months by Treatment Arm,  Progression-free Survival by Treatment Arm, Overall Response Rate by Treatment Arm

Interventions: Tremelimumab, Placebo

Phase:

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),Primary Purpose: Treatment

Primary Completion Date: January 24, 2016

Completion Date: December 31, 2019

Last  Posted Date: July 16, 2019

Location: Research Site, Scottsdale, Arizona, United States

Website Link: https://ClinicalTrials.gov/show/NCT01843374

Was this article helpful?
Dislike 0